ClinicalTrials.gg
RecruitingNCT07203378ENERGIZEUpdated Aug 20, 2026

Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu

A Phase 2 interventional study of Whole-body resistance training and aerobic exercise in Metastatic Breast Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Utah · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.

Planned enrollment
11th of 33
80 · median 34
Started
2025
with 7 others
Phase 2
7 of 33
3 open now
Registered
33rd of 33
by date

Among the 33 studies in Breast Neoplasms by University of Utah, this one is the 11th largest by planned enrollment, is one of 8 that started in 2025, is one of 7 in phase 2, and was the 33rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Breast Neoplasms by University of Utah, or all of them as a file.
02

Study summary

The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject aged ≥ 18 years
  • Diagnosis of locally advanced/unresectable or breast cancer. Note: Patients with High-Risk + breast cancer after completion of chemotherapy requiring adjuvant Enhertu are allowed at the discretion of the treating physician.
  • Has received 3 or 4 cycles of Enhertu and is expected to continue treatment for at least 12 weeks. Note: HER-2 targeted systemic therapy (e.g. Trastuzumab and/or Pertuzumab) in conjunction with Enhertu is allowed.
  • Able and willing to participate in the interventional aerobic exercise and resistance exercises.
  • Currently following standard of care requirements and willing to continue following these requirements for the duration of therapy.
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.
  • Experiencing clinical fatigue symptoms in the opinion of the investigator.
  • Subject has completed the ACSM exercise preparticipation health screening and is, in the opinion of the investigator, fit to participate in this study.

Exclusion criteria

Exclusion Criteria:

-Currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training ≥ two days per week.

  • Structured is defined as time set aside in the subject's day to workout.
  • Resistance training is defined as exercises which use weights, bands, or body weight (e.g., squats or push-ups).

AND Currently participating in structured moderate-intensity aerobic exercise for ≥ 150 minutes per week.

  • Moderate-intensity exercise is defined as activities where the subject can talk but not sing.
  • Aerobic exercise includes, but is not limited to, walking, swimming, cycling, running, rowing, hiking, and elliptical.

    • Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give , comply with the study protocol or complete the study.
    • Participants taking prohibited medications as described in Section 7.4.1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention

    Other: Whole-body resistance training and aerobic exercise

  • No intervention
    Usual Care

Interventions

  • OtherWhole-body resistance training and aerobic exercise

    A 12-week individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise routine will be provided to each study participant.

06

What researchers measure

Primary outcomes

  1. Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score from baseline to Week 13 (end of exercise intervention).

    Test the preliminary efficacy of a 12-week, home-based, unsupervised aerobic and resistance training exercise program on changes in cancer-related fatigue, in patients with a diagnosis of locally advanced/unresectable or metastatic breast cancer and patients with High-Risk HER 2+ breast cancer after completion of neoadjuvant chemotherapy who are receiving Enhertu therapy. FACIT Fatigue Scored 0 (not at all)- 4(Very Much).

    Time frame: 13 weeks

Secondary outcomes

  1. Feasibility defined as greater than 75% of all participants completing greater than 66% of all prescribed workouts from baseline to Week 13.

    Test the feasibility of the tested 12-week, home-based, unsupervised aerobic and resistance training exercise program.

    Time frame: 13 weeks

  2. Mean Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score measured every three weeks from baseline to Week 13.

    Compare the trajectory of cancer-related fatigue from baseline to Week 13 between patients receiving the exercise intervention versus not. FACIT Fatigue Scored 0 (not at all)- 4 (Very Much).

    Time frame: 13 weeks

Other outcomes

  1. Change in Functional Assessment of Cancer Therapy - Breast (FACT-B) score from baseline to Week 13.

    Evaluate the preliminary efficacy of the exercise intervention on breast cancer-related quality of life. FACT-B scored 0 (not at all)- 4 (Very Much).

    Time frame: 13 weeks

  2. Mean Functional Assessment of Cancer Therapy - Breast (FACT-B) score measured every three weeks from baseline to 13 weeks after initiation of training.

    Compare the trajectory of breast cancer-related quality of life from baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not. FACT-B scored 0 (not at all)- 4 (Very Much).

    Time frame: 13 weeks

  3. Change in the average time spent in moderate to vigorous physical activity (in minutes)

    Evaluate the preliminary efficacy of the exercise intervention on exercise engagement. At one week prior to baseline (i.e. baseline), at the midpoint of the intervention (Week 6) and during the final week of the intervention (Week 12), as measured by the Actigraph GT9x Link accelerometer.

    Time frame: 12 weeks

  4. Markers evaluating activity collected from the Actigraph, such as time spent in light activity.

    Evaluate the preliminary efficacy of the exercise intervention on exercise engagement.

    Time frame: 12 weeks

  5. Markers evaluating activity collected from the Actigraph, such as step count.

    Evaluate the preliminary efficacy of the exercise intervention on exercise engagement.

    Time frame: 12 weeks

  6. Average time spent in moderate to vigorous physical activity (in minutes) measured at baseline, Week 6, and Week 12 by the Actigraph GT9x Link accelerometer.

    Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.

    Time frame: 12 weeks

  7. Other markers evaluating activity collected daily from the Actigraph GT9x, such as step count.

    Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.

    Time frame: 12 weeks

  8. Other markers evaluating activity collected daily from the Actigraph GT9x, such as time spent in light activity.

    Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.

    Time frame: 12 weeks

  9. Change in mean PROMIS Physical Function score from baseline to Week 13.

    Evaluate the preliminary efficacy of the exercise intervention on physical function. Scored 5 (Without any difficulty)- 1 (Unable to do).

    Time frame: 13 weeks

  10. Change in the following objective measures of physical function from baseline to Week 13: 30-second chair stand.

    Evaluate the preliminary efficacy of the exercise intervention on physical function.

    Time frame: 13 weeks

  11. Change in the following objective measures of physical function from baseline to Week 13: Balance Test

    Evaluate the preliminary efficacy of the exercise intervention on physical function. The Balance Test will consist of: Participants will be instructed to stand up with their feet in three different positions (side-by-side, tandem and semi-tandem) for 10 seconds each position.

    Time frame: 13 weeks

  12. Change in the following objective measures of physical function from baseline to Week 13: 30-second maximum push-up test.

    Evaluate the preliminary efficacy of the exercise intervention on physical function.

    Time frame: 13 weeks

  13. Average physical function measured at baseline, Week 6, and Week 12 by PROMIS Physical Function score.

    Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not. Scored 5 (Without any difficulty)- 1 (Unable to do).

    Time frame: 12 weeks

  14. Other markers evaluating physical function, including 30-second chair stand.

    Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not.

    Time frame: 12 weeks.

  15. Other markers evaluating physical function, including a Balance Test.

    Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not. The Balance Test will consist of: Participants will be instructed to stand up with their feet in three different positions (side-by-side, tandem and semi-tandem) for 10 seconds each position.

    Time frame: 12 weeks.

  16. Other markers evaluating physical function, including a 30-second maximum push-up test.

    Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not.

    Time frame: 12 weeks.

  17. Change in Sit-to-Stand score patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.

    Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.

    Time frame: 13 weeks

  18. Change in handgrip strength (peripheral measures of fatigue) patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.

    Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.

    Time frame: 13 weeks

  19. Change in the number of rest-activity patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.

    Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.

    Time frame: 13 weeks

  20. Mean score for sit-to-stand patterns measured at baseline, 6-weeks, and Week 13.

    Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.

    Time frame: 13 weeks

  21. Mean score for handgrip strength patterns measured at baseline, 6-weeks, and Week 13.

    Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.

    Time frame: 13 weeks

  22. Mean number of rest-activity patterns measured at baseline, 6-weeks, and Week 13.

    Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.

    Time frame: 13 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Oct 2, 2025
StartActual
Nov 4, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07203378
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Nov 4, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Janna Espinosa
Contact
Janna.Espinosa@hci.utah.edu
801-585-0571
Roma Bhatia, MD
Contact
Roma.bhatia@hci.utah.edu
801-585-0255

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion